ChemDiv and Nerviano Medical Sciences (NMS) have previously expanded their partnership to discover and develop potential anticancer agents.
Under the terms of the collaboration, ChemDiv will receive a milestone payment for successful delivery of a lead molecule to NMS, in addition to research fees earned for discovery services.
Nikolay Savchuk, president and CEO of ChemDiv, said: “We are very pleased to be able to deliver high value to Nerviano’s oncology program applying our Discovery outsource platforms. ChemDiv’s rational approach to small molecule discovery and strengths in medicinal chemistry and preclinical biology will help to secure further success in this collaboration.”